Measles Vaccines in 1963: From Virus Culture to Childhood Vaccination

Before vaccination, measles was a common childhood infection, and complications including pneumonia and encephalitis made it much more than a brief rash. Vaccine development first required a continuing supply of identifiable viral material in the laboratory. In 1954, John Enders and Thomas Peebles at the Children's Medical Center in Boston used patients' blood or throat samples to isolate agents causing cell changes in human or monkey kidney tissue cultures.

The original paper reported changes including giant-cell formation and tested them with measles convalescent serum. Suppression of the changes by serum and specificity in antigen reactions strengthened the connection between the cultures and measles. Identification did not rely solely on seeing a particular shape under a microscope. A strain from patient David Edmonston later became an important starting point for vaccines, but isolation in 1954 was not vaccine licensing.

References: [1] [4]

Enders's team and researchers including Samuel Katz serially passed the virus through different culture conditions, seeking candidates that retained the capacity to induce immunity while reducing disease-causing ability. Live attenuated vaccines still contained virus capable of limited replication, unlike vaccines treated to inactivate the virus. Successful culture, altered laboratory properties and protection in humans were three questions needing separate verification; adaptation to culture did not itself establish suitability for widespread vaccination.

Early trials recorded fever, rash and immune responses after vaccination and explored combining vaccination with gamma globulin to lessen reactions. Morley, Katz and Krugman's 1963 paper described research involving 500 children in Imesi village and Ilesha hospital in Nigeria, comparing administration with and without gamma globulin. Differences in setting and children's nutritional status were practical issues in testing whether American experience could transfer to other populations.

References: [2] [4]

In 1963, the United States approved early measles vaccines. Merck Sharp & Dohme, part of Merck, produced a live attenuated vaccine, while companies including Pfizer pursued inactivated vaccines. That year's NIH Record documented licensing and production arrangements, showing a move from small-scale research to regulated product supply. Licenses concerned specific formulations and manufacturing systems, not a blanket approval for all future measles vaccines.

The live Edmonston B vaccine induced immunity but caused relatively prominent fever and rash reactions. Inactivated vaccine contained no virus capable of continued replication and initially appeared to offer another choice. Yet inability to replicate did not guarantee better long-term protection. Continued observation after vaccination was needed to compare the approaches; product improvements and withdrawals showed that licensing was not the endpoint of evidence accumulation.

References: [3] [4]

The inactivated measles vaccine provided inadequate protection, and some recipients were later found to develop atypical measles upon natural infection. It was ultimately withdrawn in the United States in 1967. The original live Edmonston B vaccine was also progressively replaced by further-attenuated formulations because of its relatively frequent reactions. The Schwarz-strain vaccine was introduced in 1965, and a further-attenuated strain developed by Maurice Hilleman and colleagues was licensed in 1968, reducing reactions common with the early live vaccine.

These dates mark development and regulatory changes in different products, not a single “final vaccine” completed in 1963. In 1971, the United States also approved the combined measles, mumps and rubella vaccine, addressing several immunization needs in one administration. The combined product changed service arrangements, but its measles component still rested on earlier long-term work in virus culture, attenuation and clinical observation.

References: [4]

Market entry did not mean every child gained protection in the same year. Effective adoption required reliable production, appropriate storage and transport, vaccination services reaching households and traceable records. Timing also had to account for maternal antibodies in infants that could interfere with immune responses, with strategies subsequently adjusted according to outbreaks and immunological evidence. Laboratory product performance and population coverage jointly determined disease-prevention effects.

The year 1963 should therefore be understood as an important licensing milestone for measles vaccines in the United States, not the moment measles ended worldwide. Countries differed in vaccine adoption, product choices and public-health capacity. It opened a new stage in which prevention could reduce measles burden; subsequent monitoring of protection gaps, product improvements and completion of vaccination services were all part of turning that achievement into a public-health benefit.

References: [4]